Skip to main content
OpenTrials
Completed

NCT Number: NCT02339506

Stress and the Nervous System

Models of stress such as hypoglycemia have identified that stress results the next day in decreased baroreflex sensitivity. This project will test the hypothesis that these delayed changes in autonomic nervous system function are secondary to a rise in ACTH. The investigators will infuse cosyntropin versus placebo in a double-blind, crossover study in healthy adults and measure the delayed effects on the autonomic system as measured by cardiovagal baroreflex sensitivity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

About this study

Stress has complex effects on the body's physiology. Models of stress such as hypoglycemia have identified that stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathoadrenal system acutely. Additionally, there are delayed effects of prior exposure to hypoglycemia. The day after being exposed to a hypoglycemic stimulus there are: 1) decreases in the catecholamine release to a new hypoglycemic stress; 2) decreases in the muscle sympathetic nerve activity (MSNA) response to either a new hypoglycemic challenge or transient hypotension; 3) decreases in cardiac vagal baroreflex sensitivity (BRS); and 4) increases in sensitivity to thermal pain and altered temporal summation (decreased tolerance to a repeated minimally painful stimulus). This project will test the hypothesis that these delayed changes in autonomic nervous system function are secondary to a rise in ACTH that occurs in response to stress.

Primary Aim. Infusion of ACTH (cosyntropin) will lead the next day to decreased cardiovagal baroreflex sensitivity in healthy subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must be currently healthy, BMI 18-32 kg/m2, and not be on any medications.

This study will recruit men and women. Due to concerns about estrogen's effects on hormone levels and possible contributions of menstrual symptoms on pain sensing thresholds, we will schedule the inpatient studies to avoid the early follicular phase in normally cycling women.

Subjects must have normal laboratory values for:

  • Complete blood count
  • Serum creatinine, sodium, potassium, glucose, liver enzymes
  • Urinalysis
  • Urine pregnancy test (if female)
  • Normal ECG

Exclusion criteria

We will exclude individuals with:

  • Systolic blood pressure > 140 or < 90 mm Hg
  • Diastolic blood pressure > 90 mm Hg
  • Creatinine clearance ≤ 60 mL/min, as calculated by MDRD formula
  • Known DM, CHF, CAD, PVD, CVA, MI, asthma
  • Known or history of Cushing's disease or adrenal insufficiency
  • Known neurologic disease
  • Known psychiatric disease
  • Steroid use (oral or inhaled, local or systemic injections, within the past 6 months)
  • Significant concomitant medical illnesses
  • Current excessive alcohol (>10oz ethanol/week)
  • Current use of recreational drugs
  • Current smokers
  • Current pregnancy
  • Chronic use of non-steroidal anti-inflammatory or narcotic medications
  • Evidence of ischemia or heart block on screening electrocardiogram (greater than type I-second degree heart block, left bundle branch block, or ST-T wave changes in 2 or more contiguous leads)
  • Subjects taking any prescription medications (other than oral birth control pills) or herbal medications will be excluded.

Treatment and study plan

Cosyntropin

Drug

Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.

Other names: ACTH

Placebo

Drug

Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.

Other names: Normal Saline

Primary outcomes

  1. Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique)

    Time frame: Baseline, 4-hours after infusion, 24-hours after infusion

    Cardiovagal baroreflex sensitivity will be measured with the Modified Oxford Technique before, during, and after drug infusions, to evaluate the effects of cosyntropin infusions.

Other outcomes

  1. Pain (Quantitative Sensory Testing Using a Thermal Pain Testing Device)

    Time frame: 1 day after ACTH

    Alterations in pain sensing will be evaluated pre and post with quantitative sensory testing using a thermal pain testing device, to evaluate the delayed effect of cosyntropin infusions.

  2. Hippocampal Memory (Paired Associative Learning Task)

    Time frame: 1 day after ACTH

    Hippocampal memory will be evaluated pre and post with a paired associative learning task. Face Name Associative Memory Exam (FNAME) composite score on a scale from 0-36, with 36 being the best possible score.

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Beth Israel Deaconess Medical Center

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2020
First posted
Jan 15, 2015
Registry last updated
Dec 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.